https://www.selleckchem.com/
he RIC Flu/TBI platform for lymphomas. Allogeneic stem cell transplantation is applied to patients suffering from hematological malignancies to replace the diseased hematopoietic system with cells derived from a donor stem cell graft. The majority of 10/10 matched unrelated donors are HLA-DP-mismatched and this may result in varying degrees of graft-versus-leukemia (GVL) effect with or without the occurrence of graft-versus-host disease (GVHD). Allo-HLA-reactive T cells are commonly present in the donor T-cell repertoire and therefore a very profound allo-r